Midori Nakamura

Matsumoto, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Beyond resorption: targeting osteoclast fusion and polarization to restore balanced bone remodeling.

Beyond resorption: targeting osteoclast fusion and polarization to restore balanced bone remodeling.

Journal: Frontiers in pharmacology
Published: March 03, 2026

Anabolic effects of Sost deficiency partially offset Opg deficiency-induced catabolism in cortical bone.

Anabolic effects of Sost deficiency partially offset Opg deficiency-induced catabolism in cortical bone.

Journal: Journal of bone and mineral metabolism
Published: June 05, 2025

Osteoprotegerin secretion and its inhibition by RANKL in osteoblastic cells visualized using bioluminescence imaging.

Osteoprotegerin secretion and its inhibition by RANKL in osteoblastic cells visualized using bioluminescence imaging.

Journal: Bone
Published: June 20, 2024

Osteoclast differentiation by RANKL and OPG signaling pathways.

Osteoclast differentiation by RANKL and OPG signaling pathways.

Journal: Journal of bone and mineral metabolism
Published: July 19, 2020

Sclerostin expression in trabecular bone is downregulated by osteoclasts.

Sclerostin expression in trabecular bone is downregulated by osteoclasts.

Journal: Scientific reports
Published: April 08, 2020

Osteoprotegerin-dependent M cell self-regulation balances gut infection and immunity.

Osteoprotegerin-dependent M cell self-regulation balances gut infection and immunity.

Journal: Nature communications
Published: July 14, 2019

Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis.

Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis.

Journal: PloS one
Published: May 11, 2017

A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro.

A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro.

Journal: PloS one
Published: April 23, 2017

Bone Formation Is Coupled to Resorption Via Suppression of Sclerostin Expression by Osteoclasts.

Bone Formation Is Coupled to Resorption Via Suppression of Sclerostin Expression by Osteoclasts.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Published: January 18, 2017

Pharmacokinetics of bisphosphonate.

Pharmacokinetics of bisphosphonate.

Journal: Clinical calcium
Published: October 26, 2016

Angiotensin II Stimulation of Cardiac Hypertrophy and Functional Decompensation in Osteoprotegerin-Deficient Mice.

Angiotensin II Stimulation of Cardiac Hypertrophy and Functional Decompensation in Osteoprotegerin-Deficient Mice.

Journal: Hypertension (Dallas, Tex. : 1979)
Published: October 29, 2015

Cardiac hypertrophy is exacerbated in aged mice lacking the osteoprotegerin gene.

Cardiac hypertrophy is exacerbated in aged mice lacking the osteoprotegerin gene.

Journal: Cardiovascular research
Published: October 06, 2015
Showing 1-12 of 20

Last Updated: 09/26/2026